Primary Hyperoxaluria Screening and Monitoring: Quantitative Measurement of Plasma Oxalate by Gas Chromatography-Mass Spectrometry With High Sensitivity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Plasma oxalate measurements can be used for the screening and therapeutic monitoring of primary hyperoxaluria. We developed a gas chromatography-mass spectrometry (GC-MS) assay for plasma oxalate measurements with high sensitivity and suitable testing volumes for pediatric populations. Methods: Plasma oxalate was extracted, derivatized, and analyzed by GC-MS. We measured the ion at m/z 261.10 to quantify oxalate and the 13C2-oxalate ion (m/z: 263.15) as the internal standard. Method validation included determination of the linear range, limit of blank, limit of detection, lower limit of quantification, precision, recovery, carryover, interference, and dilution effect. The cut-off value between primary and non-primary hyperoxaluria in a pediatric population was analyzed. Results: The detection limit was 0.78 μmol/L, and the linear range was up to 80.0 μmol/L. The between-day precision was 5.7% at 41.3 μmol/L and 13.1% at 1.6 μmol/L. The carryover was <0.2%. The recovery rate ranged from 90% to 110%. Interference analysis showed that Hb did not interfere with plasma oxalate quantification, whereas intralipids and bilirubin caused false elevation of oxalate concentrations. A cut-off of 13.9 μmol/L showed 63% specificity and 77% sensitivity, whereas a cut-off of 4.15 μmol/L showed 100% specificity and 20% sensitivity. The minimum required sample volume was 250 μL. The detected oxalate concentrations showed interference from instrument conditioning, sample preparation procedures, medications, and various clinical conditions. Conclusions: GC-MS is a sensitive assay for quantifying plasma oxalate and is suitable for pediatric patients. Plasma oxalate concentrations should be interpreted in a clinical context.
Abstract
Background: Plasma oxalate measurements can be used for the screening and therapeutic monitoring of primary hyperoxaluria. We developed a gas chromatography-mass spectrometry (GC-MS) assay for plasma oxalate measurements with high sensitivity and suitable testing volumes for pediatric populations. Methods: Plasma oxalate was extracted, derivatized, and analyzed by GC-MS. We measured the ion at m/z 261.10 to quantify oxalate and the 13C2-oxalate ion (m/z: 263.15) as the internal standard. Method validation included determination of the linear range, limit of blank, limit of detection, lower limit of quantification, precision, recovery, carryover, interference, and dilution effect. The cut-off value between primary and non-primary hyperoxaluria in a pediatric population was analyzed. Results: The detection limit was 0.78 μmol/L, and the linear range was up to 80.0 μmol/L. The between-day precision was 5.7% at 41.3 μmol/L and 13.1% at 1.6 μmol/L. The carryover was <0.2%. The recovery rate ranged from 90% to 110%. Interference analysis showed that Hb did not interfere with plasma oxalate quantification, whereas intralipids and bilirubin caused false elevation of oxalate concentrations. A cut-off of 13.9 μmol/L showed 63% specificity and 77% sensitivity, whereas a cut-off of 4.15 μmol/L showed 100% specificity and 20% sensitivity. The minimum required sample volume was 250 μL. The detected oxalate concentrations showed interference from instrument conditioning, sample preparation procedures, medications, and various clinical conditions. Conclusions: GC-MS is a sensitive assay for quantifying plasma oxalate and is suitable for pediatric patients. Plasma oxalate concentrations should be interpreted in a clinical context.
참고문헌 (30)
- Brzica H, "Oxalate : from the environment to kidney stones", Arh Hig Rada Toksikol, 64, pp.609~630 (2013)
- Danpure CJ, "An enzyme trafficking defect in two patients with primary hyperoxaluria type 1 : peroxisomal alanine", glyoxylate aminotransferase rerouted to mitochondria, 1989, pp.108, 1345~1352
- Williams EL, "Primary hyperoxaluria type 1 : update and additional mutation analysis of the AGXT gene", Hum Mutat, 30, pp.910~917 (2009)
- Cochat P, "Primary hyperoxaluria type 1 : indications for screening and guidance for diagnosis and treatment", Nephrol Dial Transplant, 27, pp.1729~1736 (2012)
- Cramer SD, "The gene encoding hydroxypyruvate reductase(GRHPR)is mutated in patients with primary hyperoxaluria type II", Hum Mol Genet, 8, pp.2063~2069 (1999)
- Rumsby G, "Primary hyperoxaluria", N Engl J Med, 369, pp.2163~ (2013)
- Williams EL, "The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3", Nephrol Dial Transplant, 27, pp.3191~3195 (2012)
- Greed L, "Metabolite diagnosis of primary hyperoxaluria type 3", Pediatr Nephrol, 33, pp.1443~1446 (2018)
- Porowski T, "A semi-micromethod for determination of oxalate in human plasma", Acta Pol Pharm, 60, pp.239~245 (2003)
- Hoppe B, "Simultaneous determination of oxalate, citrate and sulfate in children’s plasma with ion chromatography", Kidney Int, 53, pp.1348~1352 (1998)
- Elgstoen KBP, "Liquid chromatography-tandem mass spectrometry method for routine measurement of oxalic acid in human plasma", J Chromatogr B Analyt Technol Biomed Life Sci, 873, pp.31~36 (2008)
- Chambers MM, "A specific assay for plasma oxalate", Clin Biochem, 6, pp.22~28 (1973)
- France NC, "Measurement of plasma oxalate by capillary gas chromatography and its validation by isotope dilution mass spectrometry", J Chromatogr, 433, pp.1~7 (1988)
- Inoue Y, "Monitoring method for pre-and post-liver transplantation in patients with primary hyperoxaluria type I", J Chromatogr B Analyt Technol Biomed Life Sci, 792, pp.89~97 (2003)
- Wolthers BG, "The determination of oxalic acid in plasma and urine by means of capillary gas chromatography", Clin Chim Acta, 120, pp.87~102 (1982)
- Ladwig PM, "Sensitive spectrophotometric assay for plasma oxalate", Clin Chem, 51, pp.2377~2380 (2005)
- Xia J, "MetaboAnalyst : a web server for metabolomic data analysis and interpretation", Nucleic Acids Res, 37(Web Server issue), pp.W652~W660 (2009)
- De Nicolò A, "Matrix effect management in liquid chromatography mass spectrometry : the internal standard normalized matrix effect", Bioanalysis, 9, pp.1093~1105 (2017)
- Cortese M, "Compensate for or minimize matrix effects?", Strategies for overcoming matrix effects in liquid chromatography-mass spectrometry technique : a tutorial review. Molecules, 25, pp.3047~ (2020)
- Stokes F, "Plasma oxalate : comparison of methodologies", Urolithiasis, 48, pp.473~480 (2020)
- Assimos DG, "Re : plasma oxalate : comparison of methodologies", J Urol, 204, pp.1374~ (2020)
- Mazzachi BC, "Factors affecting measurement of urinary oxalate", Clin Chem, 30, pp.1339~1343 (1984)
- Hellman L, "Metabolism of l-ascorbic acid-1-C14 in man", J Biol Chem, 230, pp.923~930 (1958)
- Knight J, "Ascorbic acid intake and oxalate synthesis", Urolithiasis, 44, pp.289~297 (2016)
- Rolton HA, "The effect of vitamin C intake on plasma oxalate in patients on regular haemodialysis", Nephrol Dial Transplant, 6, pp.440~443 (1991)
- Wechtersbach L, "Reduction of dehydroascorbic acid at low pH", J Biochem Biophys Methods, 70, pp.767~772 (2007)
- Simpson GL, "The non-oxidative degradation of ascorbic acid at physiological conditions", Biochim Biophys Acta, 1501, pp.12~24 (2000)
- Kasidas GP, "Measurement of plasma oxalate in healthy subjects and in patients with chronic renal failure using immobilised oxalate oxidase", Clin Chim Acta, 154, pp.49~58 (1986)
- Perinpam M, "Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease", Clin Biochem, 50, pp.1014~1019 (2017)
- Costello JF, "Plasma oxalate concentrations rise in hemodialysis patients despite increased oxalate removal", J Am Soc Nephrol, 1, pp.1289~1298 (1991)